Scott Parrish, MD
Pulmonary Disease · Appleton, WINPI 1073672390
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (44.7%), education and food and beverage — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Intuitive Surgical at 47.5% of the total. Reporting peaked in 2024 at $5,979 and has fallen 92.5% since, to $449 in 2025.
Across 88 payments — averaging $134.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- Pinnacle Biologics, Inc$3K
- Johnson & Johnson$2K
- CSA Medical, Inc$146
- Inogen, Inc.$115
- Galvanize Therapeutics, Inc$105
- plus $665 from 14 others
What the payments were for
- Speaking & faculty fees$1,50013%
- Travel & lodging$5,29745%
- Food & beverage$2,45421%
- Education$2,59722%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 18 | $5,627 |
| Pinnacle Biologics, Inc | 15 | $3,417 |
| Johnson & Johnson | 20 | $1,771 |
| CSA Medical, Inc | 1 | $146 |
| Inogen, Inc. | 7 | $115 |
| Galvanize Therapeutics, Inc | 2 | $105 |
| GSK | 6 | $103 |
| Inspire Medical Systems, Inc. | 3 | $99 |
| Sanofi-aventis U.S. LLC | 1 | $85 |
| Pulmonx Corporation | 2 | $64 |
| Boehringer Ingelheim | 2 | $57 |
| Verona Pharma, Inc. | 2 | $53 |
| Steris Corporation | 1 | $38 |
| AstraZeneca | 2 | $30 |
| Covidien LP | 1 | $29 |
| Electromed, Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $22 |
| United Therapeutics Corporation | 1 | $21 |
| Insmed, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,440
- Photofrin$3,097
- MONARCH$703
- Monarch Platform$676
How this compares
$11,848 in reported general payments places this provider in the 85th percentile of 247 pulmonary disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 761 | $618,484 |
| OfevNintedanib Esylate | 38 | $515,586 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 385 | $242,948 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 247 | $142,472 |
| Spiriva RespimatTiotropium Bromide | 195 | $136,363 |
| Breo ElliptaFluticasone/Vilanterol | 82 | $52,732 |
| Dupixent SyringeDupilumab | 12 | $52,707 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 263 | $48,548 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 51 | $32,286 |
| SymbicortBudesonide/Formoterol Fumarate | 65 | $25,634 |
| Spiriva HandihalerTiotropium Bromide | 25 | $20,889 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 24 | $18,697 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 26 | $13,872 |
| Wixela InhubFluticasone Propion/Salmeterol | 81 | $13,459 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $12,726 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $57 | $913,594642 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $103 | $830,9381,139 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $30 | $57,919116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 247 pulmonary disease providers in Wisconsin.
Other pulmonary disease in Appleton
- Nicholas FreemanAppleton$10K
- Sanjeevkumar PatelAppleton$6K
- Daniel LeonardAppleton$5K
- Jonathan KurmanMilwaukee$803K
- Mouhammed RihawiMilwaukee$713K
- Hasnain BawaadamKenosha$686K
- Alfred HabelKenosha$194K
- Manar Al ShahrouriGreen Bay$61K
- Kurt HuMilwaukee$55K
- Julie BillerMilwaukee$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.